A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

B-Secur Collaborates with Texas Instruments

B-Secur today announced it has launched an electrocardiogram (ECG/EKG) solution based on the Texas Instruments (TI) AFE4950 analog front end (AFE) for photoplethysmography (PPG) and ECG/EKG sensing that will accelerate the design of next-generation consumer wearables.

The integration provides high-performing sensing capabilities for wearable devices like premium smartwatches and Wi-Fi-connected optical heart-rate monitors, and enables advanced features for identification, wellness and health monitoring in Internet of Things (IoT) devices.

It is the industry’s first solution with a fully integrated ECG/EKG and PPG signal chain that allows for synchronous sampling of cardiac activity with dry electrodes used in battery-operated products.

It follows an announcement from B-Secur that it has received U.S. Food and Drug Administration (FDA) clearance for its innovative HeartKey® ECG/EKG software.

The combination of HeartKey® and TI’s AFE4950 enables device manufacturers and partners around the world to eliminate months of R&D with a fully integrated sensor, electrical and signal processing solution. It is a key development enabling heart-health features to become widely available in the fast-paced and rapidly evolving consumer wearables sector.

The collaboration is part of B-Secur’s drive to speed up the development and adoption of high-performance biosensing solutions by device manufacturers worldwide.

Ben Carter, Chief Commercial Officer, B-Secur commented: “It is a key strategic development for B-Secur to announce this integration with Texas Instruments and our FDA-cleared HeartKey® software today. As more and more wearable and IoT devices adopt ECG/EKG technology, supplying a fully integrated, high-performance solution with Texas Instruments means our customers around the world can bring their own consumer wearable products to market quicker and with greater confidence.”

Karthik Soundarapandian, product line manager for medical imaging at TI, said: “The trend in consumer electronics is to add more health monitoring into smartwatches and other wearables. This, in combination with a patient’s medical history, can help health professionals with early detection and prevention of disease. The precision signal quality from the AFE4950-based hardware, combined with B-Secur’s algorithms, will help wearables manufacturers design solutions that make clinical-quality monitoring more accessible to a wider population.”

B-Secur’s HeartKey® consists of a suite of powerful ECG/EKG algorithms that uniquely combine user identification, health, and wellness to generate accurate data encrypted through the user’s unique heartbeat.

Cardiovascular disease (CVD) is the number one cause of death globally with an estimated 17.9 million people dying from the disease each year representing 31% of all global deaths.

SourceB-Secur
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy